Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 101.31

-2.5%

3:31 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (2655)	5/11/2011 12:42:50 AM
From: software salesperson	Read Replies (1) of 3202

from 5/10 BofA presentation rationale for rux pancreatic cancer trial: 1) animal models show heightened sensitivity to apoptosis from chemotherapeutics when JAK pathway is taken out at the same time 2) penetrate tumor 3) prevent severe cachexia development it will be a P2b study that could be registrational the endpoint will be overall survival it will be for 2nd line capecitabine + rux vs. capecitabine sales

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next